Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrandrine Tablets in Treating Interstitial Lung Disease Related to Connective Tissue Disease
NCT07319598Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Nov 2023
- Primary completion
- Oct 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tetrandrine in connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by Peking University Third Hospital. Started Nov 2023; status: recruiting.
02
Drugs
tetrandrine
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NCT07319598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07319598.